fetal stem cell therapy
Commercial- Indications
- Parkinson's Disease, Traumatic Brain Injury, Multiple Sclerosis, Cystic Fibrosis, Lupus, Rheumatoid Arthritis, Migraine Headaches, Muscular Dystrophy, Fibromyalgia
Company intelligence / Profile preview
Stem Cell of America claims to have treated over 10,000 patients since 1995 using allogenic fetal stem cells administered intravenously and subcutaneously. The company reports positive patient testimonials for a range of conditions including Parkinson's disease, lupus, and rheumatoid arthritis. They state that their treatments are safe with no reported adverse effects but do not provide peer-reviewed clinical trial data[1][3].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Stem Cell of America.